Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | INSR | P06213 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | TEK | Q02763 | 2/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 6/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592346 | 1.00 | IGF1R (0.52) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL599931 | 0.79 | AURKA (0.39) | KDRAURKAAURKB | |
| SCHEMBL6311579 | 0.79 | AURKA (0.73) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL591481 | 0.78 | CYP1A2 (0.44) | AURKAAURKB | |
| SCHEMBL6311161 | 0.72 | IGF1R (0.66) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL6312556 | 0.72 | IGF1R (0.69) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL6320480 | 0.70 | IGF1R (0.69) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL593065 | 0.70 | AURKA (0.55) | CDK2MAPK8AURKAAURKB | |
| SCHEMBL6314276 | 0.69 | IGF1R (0.66) | IGF1REGFRINSRMETCDK2 | |
| SCHEMBL6317753 | 0.69 | IGF1R (0.58) | IGF1REGFRINSRMETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | claimed |
| EP-1874760-B1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2010-10-06 | — | — | EP | claimed |
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114882-B2 | Antitumor agents; kinase inhibitors; angiogenesis inhibitors; arteriosclerosis ; antiinflammatory agents | MERCK PATENT GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| EP-1874760-B1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-1874760-B1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2010-10-06 | — | — | EP | disclosed |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | MERCK PATENT GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1874760-A1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | Merck Patent GmbH (DE) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108487-A1 | (LH-IND0L-7-YL)-( (PYRIMIDIN-2 -YL-AMINO) METHANONE DERIVATIVES AND RELATED COMPOUNDS AS IGF-RL INHIBITORS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194605-A1 | (1H-Ind0l-7-Yl)-(Pyrimidin-2-Ylamino)Methanone Derivatives and Related Compounds as Igf-R1 Inhibitors for the Treatment of Cancer | IGF1R, INHA, CCNO | IGF1R 1/4885EGFR 184/4885INSR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.